Gentler transplant offers hope for older blood cancer patients

NCT ID NCT05436561

Recruiting now Disease control Sponsor: Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

Summary

This study is testing a less intense, 'reduced conditioning' bone marrow transplant for people aged 55 and older with myeloid blood cancers like AML, MDS, and CMML. The goal is to see if using lower doses of chemotherapy drugs (melphalan, busulfan, and fludarabine) before the transplant can still control the cancer while causing fewer severe side effects. Researchers will track how long patients survive without their cancer coming back.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DISEASE-FREE SURVIVAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Blood & Marrow Transplantation Center, RuiJin Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200025, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••
Shanghai No 6 Hospital
RECRUITING

Shanghai, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

DISEASE-FREE SURVIVAL